Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Quality of life in keratoprosthesis patients

Poster Details

First Author: T. Lansini BRAZIL

Co Author(s):    S. Kwitko                    

Abstract Details


Goal - assess the quality of life in patients undergoing implantation of Dohlman-Doane keratoprosthesis.


Hospital de Clinicas de Porto Alegre


cross-sectional study, conducted with all patients submitted to implant of Dohlman-Doane keratoprosthesis type I at the Hospital de Clinicas de Porto Alegre between September 2005 and May 2013. A generic scale (SF-36) and other scale related to vision (VF-14) were applied in these patients. Patients were divided into two groups, separated by visual acuity (cutoff 1.0 LogMar or 20/200 Snellen). In both groups, the two questionnaires were compared and the results applied. The primary outcome was to assess the quality of life in these patients. Secondary outcomes were post-operative visual acuity and complication rates.


33 eyes of 26 patients. Five patients were lost to follow-up (19.23%). Questionnaires were then applied in 21 patients, analyzing their results, visual acuity and rate of complications. The average follow-up time was 56.1 ± 42.4 months (12 to 102 months). Retention rate of keratoprosthesis in this sample was 80.95%. The underlying pathologies were failure of multiple corneal transplants in 15 eyes (keratoconus, bullous keratopathy, acute glaucoma, aniridia, Acanthamoeba keratitis), alkaline burn eyes in 8, Stevens-Johnson syndrome (SJS) in 3, thermal burn in one.


In conclusion, we observed that in our sample Boston KPro implantation has the potential of significantly improving the vision-related quality of life in patients with poor prognosis. There was an improvement in quality of life in implanted type 1 Boston K-Pro, especially in patients who had a better postoperative VA.

Financial Disclosure:


Back to Poster listing